Kymera Therapeutics stated that its BroADen clinical trial of KT-621 showed that it achieved median reductions of STAT6 degradation of 94% and 98% in skin and blood in 100mg and 200mg dose groups.
Kymera Therapeutics Inc. (KYMR) shares were up more than 31% in Monday’s pre-market trade after the company announced positive results from its Phase 1b clinical trial of KT-621 in patients with moderate to severe atopic dermatitis.
Add Asianet Newsable as a Preferred Source
The company stated that its BroADen clinical trial of KT-621 showed that it achieved median reductions in STAT6 degradation of 94% and 98% in skin and blood, respectively, in the 100mg and 200mg dose groups.
Retail sentiment on Stocktwits around the Kymera stock trended in the ‘bullish’ territory at the time of writing.
Get updates to this developing story directly on Stocktwits.<
For updates and corrections, email newsroom[at]stocktwits[dot]com.<
